Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults

Recruiting · NCT04396002 · Observational (researchers observe without assigning treatment) · Lead sponsor: University of Alabama at Birmingham

View the official record on ClinicalTrials.gov →

Hypertension

Interventions studied

Contrast sensitivity under dim illuminationDark AdaptationLife Space QuestionnaireLow Luminance QuestionnaireMacular Pigment Optical Density (MPOD)Visual field under dim illumination (MAIA)

What this trial is about

Mobility refers to a person's purposeful movement through the environment from one place to another and can be conceptualized as a continuum from bed bound (immobility) on one extreme to making excursions to distant locations on the other extreme. Primary open-angle glaucoma (POAG) is a chronic, progressive optic neuropathy that can lead to gradual loss of vision in the peripheral field and central vision. Older adults with POAG have an increased risk for motor vehicle collisions and falls. Moreover, existing studies suggest that patients with POAG exhibit more postural sway while standing as measured by a balance platform and also tend to walk more slowly than those who are normally sighted and free of ocular disease. While these disturbances likely influence mobility, there has been little research directly assessing the impact of POAG on mobility. This study will assess the impact of POAG on life space (one aspect of mobility) and will determine whether difficulties with life space are associated with difficulties experienced under conditions of dim lighting.

Who can take part

Age range

18 Years to 100 Years

Sex

All (male and female)

Healthy volunteers

Yes - healthy volunteers may be accepted

Phase

Not specified

Study type

Observational (researchers observe without assigning treatment)

Inclusion criteria

Patients):
Participants that are enrolled in the Early Detection of Glaucoma Progression using a Novel Individualized Approach (IRB-300000301) or in the African Descent and Glaucoma Evaluation (ADAGES) IV: Alterations of the Lamina Cribrosa in Progression (IRB-161115004).

Exclusion criteria

Patients):
Not being enrolled in one of the following two NIH-funded studies: 1. African Descent and Glaucoma Evaluation (ADAGES) IV: Alterations of the lamina cribrosa in progression (EY026574) or 2. Early detection of glaucoma progression using a novel individualized approach (EY025756)
Inclusion Criteria (Controls):
No diagnosis of eye disease
Exclusion Criteria (Controls):
Cognitive impairment that would preclude ability to take the tests

Where it is running

1 location listed across 1 US state.

University of Alabama Birmingham - Birmingham, Alabama, United States

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →